Immunovant (IMVT) net assets (shareholders' equity)

Net assets · fiscal 2026
$852.59M

Immunovant (IMVT) had net assets of $852.59M at the end of fiscal 2026 (March 31, 2026). That is 20.5% higher than the $707.45M of fiscal 2025. Figures as of 19 Nov 2026, 00:32 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2026
$852.59M
Change on fiscal 2025
+20.5%
Growth, 5 years
+16.8% a year
Highest on record
$852.59Mfiscal 2026
Lowest on record
$7.34Mfiscal 2019
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant net assets (shareholders' equity), in more detail

Over the five fiscal years to 2026 net assets grew at a compound 16.8% a year. Across the 8 fiscal years on record (2019–2026), the highest was $852.59M in fiscal 2026 and the lowest $7.34M in fiscal 2019.

History · 8 fiscal years

Net assets by fiscal year

Immunovant net assets (shareholders' equity), year by year

Immunovant (IMVT) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2026$852.59M 20.5% up
2025$707.45M 14.5% up
2024$617.76M 70.4% up
2023$362.49M 22.8% down
2022$469.83M 20.0% up
2021$391.48M 316.2% up
2020$94.07M 1,181.8% up
2019$7.34M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Immunovant and comparable companies
CompanyNet assetsFiscal year
Immunovant IMVT$852.59M2026
Axsome Therapeutics AXSM$88.30M2025
Chemed CHE$979.41M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant net assets (shareholders' equity): questions and answers

What are Immunovant's net assets?

Immunovant (IMVT) had net assets of $852.59M at the end of fiscal 2026 (March 31, 2026). That is 20.5% higher than the $707.45M of fiscal 2025.

What is the growth rate of Immunovant's net assets?

Over the five fiscal years to 2026 net assets grew at a compound 16.8% a year.

What are the highest and lowest net assets figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was $852.59M in fiscal 2026 and the lowest $7.34M in fiscal 2019.

How is Immunovant's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Immunovant it is on record here for 8 fiscal years, 2019 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/IMVT/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.